Jennifer Litton, MD

Jennifer Litton, MD, highlights responses to talazoparib seen in patients with BRCA1/2-positive, early triple-negative breast cancer.

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the impact of PARP inhibitors in breast cancer.

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses a neoadjuvant study of talazoparib (Talzenna) for patients with BRCA1/2 mutated triple-negative breast cancer (TNBC) during the 2018 San Antonio Breast Cancer Symposium.

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the role of genetic testing in the treatment of patients with breast cancer.

Jennifer Litton, MD, associate professor, Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, discusses the results of the BETH trial.